Royalty Pharma (NASDAQ:RPRX) EVP Sells $502,027.64 in Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 9,098 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $55.18, for a total value of $502,027.64. Following the transaction, the executive vice president directly owned 9,099 shares of the company’s stock, valued at $502,082.82. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Urist also recently made the following trade(s):

• On Wednesday, May 20th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The stock was sold at an average price of $52.75, for a total transaction of $721,831.00.
• On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The shares were sold at an average price of $53.06, for a total transaction of $726,073.04.

Royalty Pharma Stock Up 2.8%

Shares of NASDAQ:RPRX opened at $56.23 on Friday. Royalty Pharma PLC has a 52-week low of $34.08 and a 52-week high of $56.50. The firm has a fifty day moving average of $52.81 and a 200 day moving average of $46.59. The firm has a market capitalization of $32.38 billion, a PE ratio of 38.25, a price-to-earnings-growth ratio of 1.55 and a beta of 0.43. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The business had revenue of $630.58 million for the quarter, compared to the consensus estimate of $881.69 million. As a group, research analysts anticipate that Royalty Pharma PLC will post 5.05 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were given a $0.235 dividend. The ex-dividend date was Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.7%. Royalty Pharma’s payout ratio is presently 63.95%.

Hedge Funds Weigh In On Royalty Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in RPRX. LM Advisors LLC purchased a new position in Royalty Pharma during the 4th quarter valued at $26,000. Blue Trust Inc. lifted its position in shares of Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 437 shares during the period. Lloyd Advisory Services LLC. bought a new stake in shares of Royalty Pharma during the 4th quarter valued at about $30,000. Private Trust Co. NA boosted its stake in shares of Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 288 shares in the last quarter. Finally, Bessemer Group Inc. increased its position in shares of Royalty Pharma by 34.7% during the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 282 shares during the period. Institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RPRX. Morgan Stanley lifted their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. lifted their price objective on Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Weiss Ratings lowered Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. Finally, UBS Group raised their price target on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $53.71.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.